150 related articles for article (PubMed ID: 37942637)
1. Recent advances on patents of
Gehlot P; Vyas VK
Expert Opin Ther Pat; 2023; 33(9):579-596. PubMed ID: 37942637
[TBL] [Abstract][Full Text] [Related]
2. Identification of 3,4-Dihydro-2
Hartuti ED; Sakura T; Tagod MSO; Yoshida E; Wang X; Mochizuki K; Acharjee R; Matsuo Y; Tokumasu F; Mori M; Waluyo D; Shiomi K; Nozaki T; Hamano S; Shiba T; Kita K; Inaoka DK
Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281290
[No Abstract] [Full Text] [Related]
3. A comprehensive review of synthetic strategies and SAR studies for the discovery of PfDHODH inhibitors as antimalarial agents. Part 1: triazolopyrimidine, isoxazolopyrimidine and pyrrole-based (DSM) compounds.
Sharma M; Pandey V; Poli G; Tuccinardi T; Lolli ML; Vyas VK
Bioorg Chem; 2024 May; 146():107249. PubMed ID: 38493638
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of 7-arylaminopyrazolo[1,5-a]pyrimidines as anti-Plasmodium falciparum, antimalarial, and Pf-dihydroorotate dehydrogenase inhibitors.
Azeredo LFSP; Coutinho JP; Jabor VAP; Feliciano PR; Nonato MC; Kaiser CR; Menezes CMS; Hammes ASO; Caffarena ER; Hoelz LVB; de Souza NB; Pereira GAN; Cerávolo IP; Krettli AU; Boechat N
Eur J Med Chem; 2017 Jan; 126():72-83. PubMed ID: 27744189
[TBL] [Abstract][Full Text] [Related]
5. In vitro resistance selections for Plasmodium falciparum dihydroorotate dehydrogenase inhibitors give mutants with multiple point mutations in the drug-binding site and altered growth.
Ross LS; Gamo FJ; Lafuente-Monasterio MJ; Singh OM; Rowland P; Wiegand RC; Wirth DF
J Biol Chem; 2014 Jun; 289(26):17980-95. PubMed ID: 24782313
[TBL] [Abstract][Full Text] [Related]
6. QSAR study on the antimalarial activity of Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitors.
Hou X; Chen X; Zhang M; Yan A
SAR QSAR Environ Res; 2016; 27(2):101-24. PubMed ID: 26911561
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, Design, and Structure⁻Activity Relationship of the Pyrimidone Derivatives as Novel Selective Inhibitors of
Xu L; Li W; Diao Y; Sun H; Li H; Zhu L; Zhou H; Zhao Z
Molecules; 2018 May; 23(6):. PubMed ID: 29794978
[TBL] [Abstract][Full Text] [Related]
8. Plasmodium falciparum dihydroorotate dehydrogenase: a drug target against malaria.
Hoelz LV; Calil FA; Nonato MC; Pinheiro LC; Boechat N
Future Med Chem; 2018 Aug; 10(15):1853-1874. PubMed ID: 30019917
[TBL] [Abstract][Full Text] [Related]
9. A Patent Review of Human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors as Anticancer Agents and their Other Therapeutic Applications (1999-2022).
Gehlot P; Vyas VK
Recent Pat Anticancer Drug Discov; 2024; 19(3):280-297. PubMed ID: 37070439
[TBL] [Abstract][Full Text] [Related]
10. Triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors with potent and selective activity against the malaria parasite Plasmodium falciparum.
Phillips MA; Gujjar R; Malmquist NA; White J; El Mazouni F; Baldwin J; Rathod PK
J Med Chem; 2008 Jun; 51(12):3649-53. PubMed ID: 18522386
[TBL] [Abstract][Full Text] [Related]
11. Medicinal chemistry approaches for the discovery of
Vyas VK; Shukla T; Sharma M
Future Med Chem; 2023 Jul; 15(14):1295-1321. PubMed ID: 37551689
[TBL] [Abstract][Full Text] [Related]
12. Identification of New Human Malaria Parasite Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors by Pharmacophore and Structure-Based Virtual Screening.
Pavadai E; El Mazouni F; Wittlin S; de Kock C; Phillips MA; Chibale K
J Chem Inf Model; 2016 Mar; 56(3):548-62. PubMed ID: 26915022
[TBL] [Abstract][Full Text] [Related]
13. Identification of novel PfDHODH inhibitors as antimalarial agents via pharmacophore-based virtual screening followed by molecular docking and in vivo antimalarial activity.
Vyas VK; Qureshi G; Ghate M; Patel H; Dalai S
SAR QSAR Environ Res; 2016 Jun; 27(6):427-40. PubMed ID: 27310104
[TBL] [Abstract][Full Text] [Related]
14. Dihydroorotate dehydrogenase: A drug target for the development of antimalarials.
Singh A; Maqbool M; Mobashir M; Hoda N
Eur J Med Chem; 2017 Jan; 125():640-651. PubMed ID: 27721149
[TBL] [Abstract][Full Text] [Related]
15. Design and tests of prospective property predictions for novel antimalarial 2-aminopropylaminoquinolones.
Clark RD; Morris DN; Chinigo G; Lawless MS; Prudhomme J; Le Roch KG; Lafuente MJ; Ferrer S; Gamo FJ; Gadwood R; Woltosz WS
J Comput Aided Mol Des; 2020 Nov; 34(11):1117-1132. PubMed ID: 32833084
[TBL] [Abstract][Full Text] [Related]
16. Deciphering Interactions between Potential Inhibitors and the
Lima Costa AH; Bezerra KS; de Lima Neto JX; Oliveira JIN; Galvão DS; Fulco UL
J Phys Chem B; 2023 Nov; 127(44):9461-9475. PubMed ID: 37897437
[TBL] [Abstract][Full Text] [Related]
17. Comparative study between the anti-P. falciparum activity of triazolopyrimidine, pyrazolopyrimidine and quinoline derivatives and the identification of new PfDHODH inhibitors.
Silveira FF; de Souza JO; Hoelz LVB; Campos VR; Jabor VAP; Aguiar ACC; Nonato MC; Albuquerque MG; Guido RVC; Boechat N; Pinheiro LCS
Eur J Med Chem; 2021 Jan; 209():112941. PubMed ID: 33158577
[TBL] [Abstract][Full Text] [Related]
18. Understanding the structural requirements in diverse scaffolds for the inhibition of P. falciparum dihydroorotate dehydrogenase (PfDHODH) using 2D-QSAR, 3D-pharmacophore and structure-based energy- optimized pharmacophore models.
Aher RB; Roy K
Comb Chem High Throughput Screen; 2015; 18(2):217-26. PubMed ID: 25543684
[TBL] [Abstract][Full Text] [Related]
19. Structural plasticity of malaria dihydroorotate dehydrogenase allows selective binding of diverse chemical scaffolds.
Deng X; Gujjar R; El Mazouni F; Kaminsky W; Malmquist NA; Goldsmith EJ; Rathod PK; Phillips MA
J Biol Chem; 2009 Sep; 284(39):26999-7009. PubMed ID: 19640844
[TBL] [Abstract][Full Text] [Related]
20. Plasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy.
Phillips MA; Rathod PK
Infect Disord Drug Targets; 2010 Jun; 10(3):226-39. PubMed ID: 20334617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]